Diabetes and Heart Disease
Program Leader: Dr. Michael Farkouh
The University of Toronto has tremendous depth and breadth in basic and clinical diabetes and cardiovascular research, with a number of BBDC-affiliated researchers interested in the intersection of these two diseases. Through funding opportunities the BBDC and University of Toronto Heart and Stroke/Richard Lewar Centres of Excellence collaborate to connect multiple scientists and institutions from diverse disciplines/technology platforms to address the most challenging research questions in the prevention and treatment of cardiovascular complications of diabetes. This program’s initial goal is to promote a Toronto-based, cross-site, clinical research collaboration on a central core platform. The initial focus is on clinical trials in the following high impact research areas: diastolic heart failure, coronary artery disease, peripheral arterial disease, and inflammatory biomarkers/novel compounds.
The BBDC and the Heart & Stroke/Richard Lewar Centres of Excellence in conjunction with the Vice-Dean of Research and International Relations, Faculty of Medicine established a funding program to support research initiatives focusing on diabetes and heart disease. The purpose of this funding program is to foster bench to bedside translational research with a focus on innovation and first-in man clinical trials. In 2014 we partnered with AstraZeneca to introduce the AstraZeneca Impact Challenge Grants – Cardiovascular/Diabetes which will provide three $250,000 research grants over the next three years to address the prevalence of cardiovascular disease in patients with diabetes.
For more information on this funding program and past recipients, see the Heart & Stroke/Richard Lewar Centres of Excellence in Cardiovascular Research website.